Scientists announced the news on Thursday that many had all but given up hope of hearing: a drug trial in Thailand had shown that an experimental vaccine could protect against HIV/AIDS, even if only to a limited extent.
Few expected the Thai trial to succeed, following as it did more than a decade of disappointment in the search for a vaccine culminating, in the failure two years ago, of a product made by the drug company Merck which looked much more promising.
But in a surprise outcome, the Thai trial conducted by the US Army and the Thai ministry of public health found that a combination of two drugs afforded a 31 percent protection against HIV infection. The result was even more surprising as the two vaccines used in combination, ALVAC and AIDSVAX, had not proven effective on their own. AIDSVAX flopped in trials in the US and also when it was given to 2,500 drug users at risk of HIV infection in Thailand.
Of the 16,000 male and female HIV-negative volunteers who took part in the biggest-ever AIDS vaccine trial, half were randomly assigned the combined vaccine and the other half a dummy injection.
All participants had been counseled about protecting themselves and given condoms and treatment for sexually transmitted infections to reduce their chances of picking up the virus. Of the first group, 51 were infected. Of the second, 74 became HIV-positive.
The immediate reaction from AIDS scientists and campaigners came like a shriek of joy. “This is the first HIV vaccine candidate to successfully reduce the risk of HIV infection in humans,” said Lieutenant General Eric Schoomaker, the US army’s surgeon general. “We are very excited and pleased with the outcome of this trial and congratulate all those who participated in it.”
“This is a historic day in the 26-year quest to develop an AIDS vaccine,” said Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, an alliance of research organizations and funders including the Gates Foundation. Warren Mitchell, executive director of the AIDS Vaccine Advocacy Coalition, called it a historic milestone.
But all recognized the enormous amount still to do if a promising trial result is to be turned into a routine vaccination. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in the US, which part-funded the trial, said he was surprised and pleased by the outcome, but warned it was “not the end of the road.” “It gives me cautious optimism about the possibility of improving this result,” he said.
The trial has shown evidence that a “prime boost strategy,” one vaccine followed later by the other,
using two vaccines made of synthetic fragments of HIV based on subtypes B (common in the US and Europe)
and E (common in Thailand and Southeast Asia) can work. The full results will
be presented at an AIDS vaccine conference in Paris next month.
The big unanswered question is why it happened, how the two vaccines together can work where singly they do not.
“Now we need to understand how some of the participants in this trial were in some way protected,” said Robin Shattock, professor of cellular and molecular infection at St George’s, University of London. “Once we understand what worked we can build on that to develop more effective vaccines.”
Jasmina Saric of the department of biomolecular medicine at Imperial College London said the combined vaccines seem to work on “a molecular weak point” of the virus. She said a more protective vaccine would have to be combined with existing prevention efforts.
The next steps are more analysis, more research and more trials. If efficacy had reached more than 50 percent the vaccine combination would have been submitted to the Thai authorities for a license. There is some way to go yet, and much to do if the approach is to be adapted to make a vaccine that works in Africa, where the strain is different and the need is greatest. The ALVAC and AIDSVAX approach may not, in the end, be the vaccine that saves the planet from AIDS, but this is one step further to one that will.
In late October of 1873 the government of Japan decided against sending a military expedition to Korea to force that nation to open trade relations. Across the government supporters of the expedition resigned immediately. The spectacle of revolt by disaffected samurai began to loom over Japanese politics. In January of 1874 disaffected samurai attacked a senior minister in Tokyo. A month later, a group of pro-Korea expedition and anti-foreign elements from Saga prefecture in Kyushu revolted, driven in part by high food prices stemming from poor harvests. Their leader, according to Edward Drea’s classic Japan’s Imperial Army, was a samurai
Located down a sideroad in old Wanhua District (萬華區), Waley Art (水谷藝術) has an established reputation for curating some of the more provocative indie art exhibitions in Taipei. And this month is no exception. Beyond the innocuous facade of a shophouse, the full three stories of the gallery space (including the basement) have been taken over by photographs, installation videos and abstract images courtesy of two creatives who hail from the opposite ends of the earth, Taiwan’s Hsu Yi-ting (許懿婷) and Germany’s Benjamin Janzen. “In 2019, I had an art residency in Europe,” Hsu says. “I met Benjamin in the lobby
April 22 to April 28 The true identity of the mastermind behind the Demon Gang (魔鬼黨) was undoubtedly on the minds of countless schoolchildren in late 1958. In the days leading up to the big reveal, more than 10,000 guesses were sent to Ta Hwa Publishing Co (大華文化社) for a chance to win prizes. The smash success of the comic series Great Battle Against the Demon Gang (大戰魔鬼黨) came as a surprise to author Yeh Hung-chia (葉宏甲), who had long given up on his dream after being jailed for 10 months in 1947 over political cartoons. Protagonist
A fossil jawbone found by a British girl and her father on a beach in Somerset, England belongs to a gigantic marine reptile dating to 202 million years ago that appears to have been among the largest animals ever on Earth. Researchers said on Wednesday the bone, called a surangular, was from a type of ocean-going reptile called an ichthyosaur. Based on its dimensions compared to the same bone in closely related ichthyosaurs, the researchers estimated that the Triassic Period creature, which they named Ichthyotitan severnensis, was between 22-26 meters long. That would make it perhaps the largest-known marine reptile and would